Hyperprogression
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial (NCT07274384) | Università Vita-Salute San Raffaele | 2026-01-01 |
| Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy (NCT06276088) | Nanfang Hospital, Southern Medical University | 2024-02-18 |
Track Hyperprogression automatically
Every clearance here is in the API, with alerts when new ones post.